drugset / Trial / NCT04621669

Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride

NCT04621669

Phase 1 Completed 36 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of digoxin, Rosuvastatin calcium and metformin hydrochloride.

Timeline

Start
2021-01-08
Primary completion
2021-09-08
Completion
2021-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.25 mg
Subject Metformin Small molecule 500 mg
Subject Rezvilutamide Small molecule 240 mg
Subject Rosuvastatin Small molecule 10 mg

Indications

No indication recorded.